Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials
Open accessThe DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To study in more depth the relationship between type, dose, or duration of methylphenidate offered to children and adolescents with attention deficit hyperactivity disorder and their risks of gastrointestinal adverse events based on our Cochrane systematic review. METHODS AND FINDINGS: We use data from our review including 185 randomised clinical trials. Randomised parallel-group trials and cross-over trials reporting gastrointestinal adverse events associated with methylphenidate were included. Data were extracted and quality assessed according to Cochrane guidelines. Data were summarised as risk ratios (RR) with 95% confidence intervals (CI) using the inverse variance method. Bias risks were assessed according to domains. Trial Sequential Analysis (TSA) was used to control random errors. Eighteen parallel group trials and 43 cross-over trials reported gastrointestinal adverse events. All trials were at high risk of bias. In parallel group trials, methylphenidate decreased appetite (RR 3.66, 95% CI 2.56 to 5.23) and weight (RR 3.89, 95% CI 1.43 to 10.59). In cross-over trials, methylphenidate increased abdominal pain (RR 1.61, 95% CI 1.27 to 2.04). We found no significant differences in the risk according to type, dose, or duration of administration. The required information size was achieved in three out of four outcomes. CONCLUSION: Methylphenidate increases the risks of decreased appetite, weight loss, and abdominal pain in children and adolescents with attention deficit hyperactivity disorder. No differences in the risks of gastrointestinal adverse events according to type, dose, or duration of administration were found.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 PRISMA flow chart [34].](https://figures.cochat.ai/paper-figures/8a9accac8f8e4b4489880cf7a4af68f6/gastrointestinal-adverse-events-during-methylphenidate-treatment-of-children-and-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A meta-analysis found that children and adolescents on methylphenidate were 50% more likely to report abdominal pain (46 studies, over 4,600 youths) and over three times more likely to experience decreases in appetite (52 studies, over 4,800 youths) and weight (7 studies, over 850 youths) (Holmskov et al., 2017).”
From The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder (2021) · cites this paper as Holmskov et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, methylphenidate, the first line treatment for ADHD, increases the risks of abdominal pain in ADHD patients45.”
From Association between attention-deficit/hyperactivity disorders and intestinal disorders: A systematic review and Meta-analysis (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A meta-analysis found that children and adolescents on methylphenidate were 50% more likely to report abdominal pain (46 studies, over 4,600 youths) and over three times more likely to experience decreases in appetite (52 studies, over 4,800 youths) and weight (7 studies, over 850 youths) (Holmskov et al., 2017).”
From The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder (2021) · cites this paper as Holmskov et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“A meta-analysis found that children and adolescents on methylphenidate were 50% more likely to report abdominal pain (46 studies, over 4,600 youths) and over three times more likely to experience decreases in appetite (52 studies, over 4,800 youths) and weight (7 studies, over 850 youths) (Holmskov et al., 2017).”
From The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder (2021) · cites this paper as Holmskov et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223 · cited 2×
“Our review also has a number of strengths: first of all, it was conducted as a Cochrane review following the instructions from the Cochrane Handbook [24] and the PRISMA guidelines [34].”
BackgroundMethodDiagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzem, E. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0655 · Cited by 8,477
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538
Self-citationKjaergard, L. L., Villumsen, J., & Gluud, C. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,283
Self-citationPrevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis
Thomas, R., Sanders, S., Doust, J., Beller, E., & Glasziou, P. (2015) · Pediatrics · doi:10.1542/peds.2014-3482 · Cited by 1,976
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Wetterslev, J., Thorlund, K., Brok, J., & Gluud, C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.013 · Cited by 1,881
Self-citationPliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765 · cited 2×
“Other studies suggest switching to another stimulant medication if the child experience adverse events [7,12].”
BackgroundAndrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.03.013 · Cited by 1,416 · cited 2×
“We assessed and graded the quality of the evidence according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) [13,26].”
MethodBrok, J., Thorlund, K., Gluud, C., & Wetterslev, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.10.007 · Cited by 1,113
Self-citation
Research works printed but not linked: 4
- E Taylor, 2009, Attention deficit hyperactivity disorder The NICE guideline on diagnosis and management of ADHD in children, young people and adults, National Clinical Practice Guideline Number 72. Br Psychol Soc R Coll Psychiatr
- K Thorlund, 2011, User manual for trial sequential analysis (TSA), Cph Trial Unit Cent Clinial Interv Res, 2011, 1
- The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.3. 2014.
- Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines, Third Edition. 2011(3).
Cited by
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.022 · Cited by 1,545
“A meta-analysis found that children and adolescents on methylphenidate were 50 % more likely to report abdominal pain (46 studies, over 4600 youths) and over three times more likely to experience decreases in appetite (52 studies, over 4800 youths) and weight (7 studies, over 850 youths) (Holmskov et al., 2017).”
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Kazda, L., Bell, K., Thomas, R., McGeechan, K., Sims, R., & Barratt, A. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.5335 · Cited by 219
ADHD: Reviewing the Causes and Evaluating Solutions
Núñez-Jaramillo, L., Herrera-Solís, A., & Herrera-Morales, W. V. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030166 · Cited by 143
“A meta-analysis on gastrointestinal adverse effects of methylphenidate reported increased risk of decreased appetite, weight loss, and abdominal pain in children and adolescents under this pharmacological treatment [149].”
BackgroundA systematic meta-review of systematic reviews on attention deficit hyperactivity disorder
Chaulagain, A., Lyhmann, I., Halmøy, A., Widding‐Havneraas, T., Nyttingnes, O., Bjelland, I., & Mykletun, A. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.2451 · Cited by 110
Ming, X., Chen, N., Ray, C., Brewer, G., Kornitzer, J., & Steer, R. A. (2018) · Child Neurology Open · doi:10.1177/2329048x18786799 · Cited by 64
Wang, L.-J., Yang, C.-Y., Kuo, H.-C., Chou, W.-J., Tsai, C.-S., & Lee, S.-Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020227 · Cited by 58
“ADHD medications have been associated with risks of decreased appetite, weight loss, and abdominal pain in children and adolescents [48].”
BackgroundNanda, A., Janga, L. S. N., Sambe, H. G., Yasir, M. B., Man, R. K., Gogikar, A., & Mohammed, L. (2023) · Cureus · doi:10.7759/cureus.45995 · Cited by 74
“Moreover, both immediate-release and extended-release forms of MPH had similar risk profiles [23].”
BackgroundWang, L., Tsai, C., Chou, W., Kuo, H., Huang, Y., Lee, S.-Y., Dai, H.-Y., Yang, C.-Y., Li, C.-J., & Yeh, Y. (2024) · Nutrients · doi:10.3390/nu16142260 · Cited by 35
“Nonetheless, MPH is known to bring about common adverse effects in children and adolescents, including reduced appetite, weight loss, and abdominal discomfort [40,41].”
BackgroundApproach to Evaluating and Managing Adult Attention-Deficit/Hyperactivity Disorder in Primary Care
Huang, H. Y., Huang, H., Spottswood, M., & Ghaemi, S. N. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000248 · Cited by 27
Leader, G., Dooley, E., Whelan, S., Gilroy, S. P., Chen, J. L., Barton, A. F., Coyne, R., & Mannion, A. (2021) · Developmental Neurorehabilitation · doi:10.1080/17518423.2021.1964005 · Cited by 24
“methylphenidate often endorse higher rates of abdominal discomfort and diarrhea, reduced appetite, and weight loss.(30,31)”
BackgroundDenyer, H., Ramos‐Quiroga, J. A., Folarin, A., Ramos, C., Nemeth, P., Bilbow, A., Woodward, E., Whitwell, S., Müller, U., Larsson, H., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04429-6 · Cited by 22
“Side effects reported to ADHD medication include changes to sleep behaviours (such as reduced total sleep time and delayed onset of sleep [26]), reduction in appetite and weight [27, 28]) and hypertension [10, 13, 28].”
BackgroundHypertonic Saline in Bronchiolitis and Type I Error: A Trial Sequential Analysis
Harrison, W. N., Angoulvant, F., House, S. A., Gajdos, V., & Ralston, S. L. (2018) · PEDIATRICS · doi:10.1542/peds.2018-1144 · Cited by 22
Huang, Y., Yeh, C., Chen, C.-H., Shang, C., & Gau, S. S. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0104 · Cited by 21
Baweja, R. K., Faraone, S. V., Childress, A. C., Weiss, M. D., Loo, S. K., Wilens, T. E., & Waxmonsky, J. G. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0022 · Cited by 18
“Sleep disruption, appetite and weight loss, and abdominal pain are common side effects associated with stimulant use (Holmskov et al., 2017, Kidwell et al., 2015).”
Does Methylphenidate Work in Children and Adolescents with Attention Deficit Hyperactivity Disorder?
Ribeiro, J. P., Arthur, E. J., Gluud, C. N., Simonsen, E. H., & Storebø, O. J. (2021) · Pediatric Reports · doi:10.3390/pediatric13030050 · Cited by 21
“The 2015 Cochrane review by Storebø and colleagues [7] associated the use of short-term methylphenidate for ADHD in children and adolescents with a risk increase of appetite decline, weight loss, and abdominal pain [24].”
BackgroundSelf-citationKurokawa, S., Nomura, K., Miyaho, K., Sanada, K., Iwamoto, C., Naraoka, M., Yoneda, S., Tomizawa, Y., Sawae, Y., Iwanaga, R., et al. (2021) · Autism Research · doi:10.1002/aur.2549 · Cited by 13
“It is important to note that the GI symptoms may have been partly influenced by the medication which the participants were receiving, as GI symptoms such as decreased appetite and abdominal pain are known as common side effects especially to stimulants (Holmskov et al., 2017).”
BackgroundEfficacy and Safety of Centanafadine for ADHD Treatment in Children: A Randomized Clinical Trial
Ward, C. L., Wilens, T. E., Jin, N., Turkoglu, O., Skubiak, T., & Childress, A. C. (2025) · Pediatrics Open Science · doi:10.1542/pedsos.2024-000349 · Cited by 14
Attention Deficit Hyperactivity Disorder in Athletes
Ciocca, M. F. (2019) · Clinics in Sports Medicine · doi:10.1016/j.csm.2019.05.004 · Cited by 17
Kaalund-Brok, K., Houmann, T., Hebsgaard, M. B., Lauritsen, M.-B. G., Lundstrøm, L. H., Grønning, H., Darling, L., Reinert-Petersen, S., Petersen, M. A., Jepsen, J. R. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253727 · Cited by 13
Ng, R. W. Y., Chen, Z., Yang, L., Wong, O. W. H., Leung, A. S. Y., Tsui, K. W., Kwok, N. M. W., Tang, L. H. Y., Cheung, P. M. H., Chan, P. K. S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04303-x · Cited by 13
“On the other hand, methylphenidate, the first line treatment for ADHD, increases the risks of abdominal pain in ADHD patients 45 .”
Teachers’ role and attitudes concerning ADHD medication: A qualitative analysis
Sluiter, M. N., Wienen, A. W., Thoutenhoofd, E. D., Doornenbal, J. M., & Batstra, L. (2019) · Psychology in the Schools · doi:10.1002/pits.22270 · Cited by 9
Rodríguez, A. M. V. (2020) · Revista Iberoamericana de Psicología · doi:10.33881/2027-1786.rip.13202 · Cited by 12
ADHS im Kindes- und Jugendalter. Update 2020
Popow, C., & Ohmann, S. (2020) · Pädiatrie & Pädologie · doi:10.1007/s00608-020-00789-y · Cited by 8
Batstra, L., Foget, L., van Haeringen, C., Meerman, S. T., & Thoutenhoofd, E. D. (2020) · Scandinavian Journal of Child and Adolescent Psychiatry and Psychology · doi:10.21307/sjcapp-2020-001 · Cited by 7
“life today gain the status of cultural memes, albeit perhaps as an unintended consequence of such research (37).”
Backgroundde Oliveira, V. F. L., Moreira, D. J. S., da Fonseca, J. B., Rossi, K., Vasconcelos, S. D. S., Dias, C. A. G. D. M., de Oliveira, E., Dendasck, C. V., de Araújo, M. H. M., & Fecury, A. A. (2021) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/health/methylphenidate-a-review · Cited by 6
From Structural Disparities to Neuropharmacology
Khoury, N. M., Radonjić, N. V., Albert, A. B., & Faraone, S. V. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.002 · Cited by 6
Zang, L., Yin, H., Chen, L., Da-qing, H., Jin, H., Yang, N., Shi, X., Liang, L., Liu, M., Fan, H. S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0645-z · Cited by 7
Chen, Y., Li, Q., Han, Y., Hong-mei, J., Gu, M., Bian, R., Ding, W., Cheng, J., & Mu, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00742-8 · Cited by 6
Attention-Deficit/Hyperactivity Disorder
Leffa, D. T., & Rohde, L. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-76136-3_28 · Cited by 4
Singh, S., Thakur, R., Kumar, K., & Dogra, A. (2024) · The Open Neuroimaging Journal · doi:10.2174/0118744400326671241002074115 · Cited by 3
Boonchooduang, N., Louthrenoo, O., Likhitweerawong, N., Kunasol, C., Nawara, W., Thonusin, C., Chattipakorn, N., & Chattipakorn, S. C. (2025) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2025.07.017 · Cited by 3
Herrera-Morales, W. V., Ramírez-Lugo, L., Cauich-Kumul, R., Murillo‐Rodríguez, E., & Núñez-Jaramillo, L. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220509155413 · Cited by 4
Ram, T. R., Mu, C., MacEachern, S. J., & Shearer, J. (2026) · Antioxidants · doi:10.3390/antiox15060764 · Cited by 3
“While mitochondrial dysfunction is well known to contribute to the issue, the cause of gastrointestinal distress in both autism and ADHD is likely multifactorial and includes diet, sleep, stress, behavioral factors, gut–brain interactions, gut microbiota, and medication use [158].”
Constipation in Children with Autism: A Comprehensive Review
Chogle, A. S., Wong, G., & Megerian, J. T. (2024) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-024-00304-6 · Cited by 3
“Despite the use of stimulants in ASD with co-occurring ADHD, which theoretically could aid constipation by stimulating gut motility, studies have not demonstrated significant improvement in constipation symptoms (37).”
L‐ and D‐threo ethylphenidate concentrations, pharmacokinetics, and pharmacodynamics in horses
Knych, H. K. D., McKemie, D. S., Seminoff, K., Hartmann, P., Hovda, L. R., & Benson, D. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2408 · Cited by 2
Remote monitoring of wide-ranging real-world changes in adults following ADHD medication initiation
Zhang, Y., Barnes, A. E., Veerakanjana, K., Denyer, H., Sankesara, H., Marriott, H., Rocks, P., Gerboni, G., Mortera, A., Müller, U., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03764-y · Cited by 1
de Oliveira, V. F. L., Moreira, D. J. S., da Fonseca, J. B., Rossi, K., Vasconcelos, S. D. S., Dias, C. A. G. D. M., de Oliveira, E., Dendasck, C. V., de Araújo, M. H. M., & Fecury, A. A. (2021) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/salud/metilfenidato-una-revision · Cited by 1
Metilfenidato: Propiedades, aplicaciones y controversias
Calvi, J. P. Q., & Cornejo, G. S. E. (2022) · Revista de Psicología · doi:10.36901/psicologia.v12i1.1479 · Cited by 2
Pugliesi, A., Mehta, N., Silva, D. G., López, J. P. K., Fuerte, C. A. L., Núñez-Ordoñez, N., Krimon, S., Kotb, O., Rodríguez-Martínez, S. A., Lima, J., et al. (2022) · Principles and Practice of Clinical Research Journal · doi:10.21801/ppcrj.2022.82.7 · Cited by 1
Sluiter, M. N., Bos, E. H., Doornenbal, J. M., de Jonge, P., & Batstra, L. (2023) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000704 · Cited by 1
Broken Brains or Flawed Studies? an Update on Leo and Cohen's Critical Review of ADHD Neuroimaging
Marley, C., O'Leary, A. M., & Nikopoulou, V. A. (2018) · The Journal of mind and behavior · Cited by 1
de Oliveira, V. F. L., Moreira, D. J. S., da Fonseca, J. B., Rossi, K., Vasconcelos, S. D. S., Dias, C. A. G. D. M., de Oliveira, E., Dendasck, C. V., de Araújo, M. H. M., & Fecury, A. A. (2021) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/gesundheit/methylphenidat-ein-rueckblick
de Oliveira, V. F. L., Moreira, D. J. S., da Fonseca, J. B., Rossi, K., Vasconcelos, S. D. S., Dias, C. A. G. D. M., de Oliveira, E., Dendasck, C. V., de Araújo, M. H. M., & Fecury, A. A. (2021) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/salute/metilfenidato-una-recensione
de Oliveira, V. F. L., Moreira, D. J. S., da Fonseca, J. B., Rossi, K., Vasconcelos, S. D. S., Dias, C. A. G. D. M., de Oliveira, E., Dendasck, C. V., de Araújo, M. H. M., & Fecury, A. A. (2021) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/sante/metilfenidato-una-revisione
Discursos de la hiperactividad: biopoder y vida cotidiana de niños y niñas con diagnóstico de TDAH
Rodríguez, V., & María, Á. (2021)
de Oliveira, V. F. L., Moreira, D. J. S., da Fonseca, J. B., Rossi, K., Vasconcelos, S. D. S., Dias, C. A. G. D. M., de Oliveira, E., Dendasck, C. V., de Araújo, M. H. M., & Fecury, A. A. (2021) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/ru/84392
Revista de Psicología Volumen 12, Número 1, Enero - Junio 2022
Pablo, U. C. S. (2022) · Revista de Psicología · doi:10.36901/psicologia.v12i1.1470
Uso do metilfenidato em crianças e adolescentes com TDAH: uma revisão sobre riscos e benefícios
Maurilio, M. M., de Camargo, R. W., & de Bitencourt, R. M. (2023) · Revista Neurociências · doi:10.34024/rnc.2023.v31.14409 · Cited by 6
“K-cramps”: ketamine misuse and abdominal pain
Akintimehin, A. O., & Hoare, J. M. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102928
Mäkinen, J. (2024) · Theseus (Ammattikorkeakoulujen)
Kwong, C. (2023) · TSpace (University of Toronto)
Seasonality and changes in ADHD medication sales to pharmacies in Poland from 2018 to 2023
Rzeszutek, M., & Wolańczyk, T. (2026) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.905
“A meta-analytic data indicate that methylphenidate is associated with an increased risk of delayed sleep onset [16], decreased appetite and weight [17], elevated systolic blood pressure (SBP) and heart rate (HR) [18], as well as reduced expected height gains [19].”
Yao, J., Gao, X., Zhu, L., Wang, L., Chen, Q., Liang, W., Feng, H., You, T., Wei, C., Liu, Y., et al. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05079-8
Amiri, D., Shah, S. J., Briziarelli, L., Amiri, S., & Karlsson, B. (2026) · Metabolites · doi:10.3390/metabo16080527
“ADHD medications remain effective for core symptoms, but they also influence appetite, weight, sleep, cardiovascular physiology, and tolerability profiles [8,9,18].”
Blake, S., Cannon, H., & Shantikumar, S. (2026) · Journal of Attention Disorders · doi:10.1177/10870547261469626
Şen, N., & Tek, N. A. (2026) · Nutrients · doi:10.3390/nu18193176
“Psychostimulant treatment, particularly methylphenidate, may suppress appetite and contribute to weight loss in children and adolescents with ADHD [27].”
Białek-Dratwa, A., Szymańska, D., Łuszczki, E., Staśkiewicz‐Bartecka, W., Grot, M., Górnik-Horn, K., Gudej, S., Emczyńska‐Seliga, E. E. V., Emich‐Widera, E., Paprocka, J., et al. (2026) · Annales Academiae Medicae Silesiensis · doi:10.18794/aams/237571
“Wpływ diety na oś jelitowo-mózgową, mikroflorę jelitową i procesy zapalne pozostaje przedmiotem badań i może mieć znaczenie kliniczne [56,62,63,91,104,110,111,112].”
Investigating Potential Adverse Drug Reactions of Lisdexamfetamine Using Sequence Symmetry Analysis
Jensen, T. L., Thysen, S. M., Jimenez‐Solem, E., Jørgensen, A., Jensen, C. B., Pedersen, H. K., Osler, M., Nielsen, M., & Lund, L. C. (2026) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70316
Metadata
- Authors
- Holmskov, M., Storebø, O. J., Moreira-Maia, C. R., Ramstad, E., Magnusson, F. L., Krogh, H. B., Groth, C., Gillies, D., Zwi, M., Skoog, M., Gluud, C., & Simonsen, E.
- Affiliations
- Region Zealand (DK)
- University of Southern Denmark (DK)
- Herlev Hospital (DK)
- Western Sydney Local Health District (AU)
- Whittington Hospital (GB)
- Copenhagen University Hospital (DK)
- University of Copenhagen (DK)
- Corresponding author
- Holmskov, Mathilde
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-06-15
- Volume
- 12
- Issue
- 6
- Pages
- e0178187
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5472278
- OpenAlex
- W2626181987
- Semantic Scholar
- 552c3937324efa16221d560652484c71a322ed8f
- Cited by
- 58
- References
- 46
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 17 · 2020: 5 · 2019: 4 · 2018: 4
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Department for International Development
- Lundbeckfonden
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Universidade Federal do Rio Grande do Sul
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- methylphenidate, attention deficit hyperactivity disorder, gastrointestinal adverse effects, appetite loss, weight loss, abdominal pain, children and adolescents, stimulant medication, dose and duration effects
- MeSH terms
- Adolescent, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Dose-Response Relationship, Drug, Female, Gastrointestinal Diseases, Humans, Male, Methylphenidate, Odds Ratio, Randomized Controlled Trials as Topic, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.